• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Managing Neutropenia in Patients With Soft Tissue Sarcomas

Article

Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.

Using prophylaxis with biosimilar granulocyte colony-stimulating factor (G-CSF) can reduce the severity of neutropenia in patients with soft tissue sarcoma, according to a study published in Supportive Care in Cancer.

For both early and advanced settings in soft tissue sarcoma, anthracycline and ifosfamide-based chemotherapy is a widely used regimen, and prophylaxis with G-CSF is usually needed to reduce the severity of chemotherapy-induced neutropenia. Italian researchers set out to determine the efficacy and safety of using the biosimilar G-CSF filgrastim in these patients.

A total of 67 patients receiving biosimilar filgrastim (US: Zarxio; Europe: Zarzio), originator filgrastim (Granulokine, Neupogen), and lenograstim (Myelostim; not approved in the United States) as primary prophylaxis were analyzed. They received a total of 360 cycles of therapy and were analyzed retrospectively.

The researchers determined that biosimilar G-CSF was effective in preventing febrile neutropenia and reducing the need for hospitalization in patients with soft tissue sarcoma undergoing epirubicin and ifosfamide treatment. Febrile neutropenia occurred in 44% of patients on biosimilar filgrastim, 40% of patients on originator filgrastim, and 45.5% of patients in the lenograstim group.

Safety profiles across the 3 groups were similar. However, using biosimilar filgrastim achieved savings of €225.25 ($251.50) over originator filgrastim and €262 ($292.54) over lenograstim.

Biosimilar G-CSF “proved comparable to its reference products from both a clinical and cost-effective standpoint,” the authors concluded.

Related Videos
Nihar Desai, MD, MPH
Dr Toon Van Gorp
Andrew Kuykendall, MD, Moffitt Cancer Center
Barry Byrne, MD
Giulio Cossu, MD
Dr Toon Van Gorp
5 experts are featured in this series
5 experts are featured in this series
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.